Mirtazapin Ratiopharm® (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Ratiopharm®, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral, buccal and sublingual use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Ratiopharm® as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapin Ratiopharm® acts within the antidepressant drug class to address mood disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adults. - Treatment‑resistant depression: may be considered when first‑line agents are insufficient. - Adjunctive therapy for bipolar depressive episodes: can be used under specialist supervision to manage depressive phases.

Mirtazapin Ratiopharm® may cause a range of adverse reactions.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypersensitivity reactions including anaphylaxis - Suicidal thoughts or behavior, especially early in treatment - Hepatic dysfunction or jaundice

Before prescribing Mirtazapin Ratiopharm®, clinicians should consider several safety aspects.

- Monitor weight: patients often experience increased appetite and weight gain. - Assess for suicidal ideation: watch for emergence of suicidal thoughts, particularly in early treatment. - Evaluate hepatic function: use caution in patients with liver impairment. - Review concomitant CNS depressants: combined use may enhance sedation. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at room temperature (below 25°C): keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapin Ratiopharm® can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible additive hypotensive effect. - Anticholinergic drugs: heightened anticholinergic burden. - Carbamazepine or phenytoin: may reduce mirtazapine concentrations. - Warfarin: monitor INR for possible alteration of anticoagulation. - Lithium: observe for increased central nervous system effects.